Article
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Leukemia research - 1 Sept 2013
Stauffer Larsen Thomas, Iversen Katrine F, Hansen Esben, Mathiasen Anders Bruun, Marcher Claus, Frederiksen Mikael, Larsen Herdis, Helleberg Inge, Riley Caroline Hasselbalch, Bjerrum Ole W, Rønnov-Jessen Dorthe, Møller Michael Boe, de Stricker Karin, Vestergaard Hanne, Hasselbalch Hans Carl
Abstract excerpt
Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n=102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.